Sirona Biochem Corp.
  • Sirona Biochem (SBM) will be presenting its latest anti-aging technology, TFC-1326, at the upcoming BIO International 2023 conference in Boston
  • The conference, which is the largest gathering worldwide for the biotech industry, will take place from June 5-8, 2023
  • TFC-1326 is also a potent antioxidant and anti-inflammatory agent, which helps prevent further signs of aging
  • Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology
  • Sirona Biochem Corp. (SBM) opened trading at C$0.125 per share

Sirona Biochem (SBM) will be presenting its latest anti-aging technology, TFC-1326, at the upcoming BIO International 2023 conference in Boston.

The conference, which is the largest gathering worldwide for the biotech industry, will take place from June 5-8, 2023. Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, will present the company’s latest technology.

About anti-aging technology

The company reports that its TFC-1326 is a revolutionary anti-aging compound that has demonstrated exceptional results in recent clinical studies.

It is based on Sirona Biochem’s proprietary platform technology. It employs a novel approach to addressing the underlying causes of aging. When used in a facial cream, TFC-1326 rejuvenates aged skin, increasing density, tightening, reducing sagging, and boosting radiance.

TFC-1326 is also a potent antioxidant and anti-inflammatory agent, which helps prevent further signs of aging. TFC-1326 can be a stand-alone product for anti-aging or an adjunctive option to Botox and dermal filler treatments depending on consumer goals.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. It specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. 

Sirona Biochem Corp. (SBM) opened trading at C$0.125 per share.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.